Bobby Shah

Biobeat Technologies Names Raymond W. Cohen as Chairman of the Board of Directors Tel Aviv, Israel & Miami, Florida, Aug. 21, 2025 (Global Newswire) – BioBeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, today announced the appointment of Raymond W. Cohen as its Chairman of the Board of Directors. Biobeat developed and has received FDA clearance for an easy-to-apply “patch” device that can collect, record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters, including continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output. “We welcome Raymond W. Cohen as our new Chairman,” said Arik Ben Ishay, co-founder and CEO of Biobeat. “Ray’s extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology.” “Biobeat has accomplished what has been an elusive goal for many – a clinically validated and FDA cleared cuff-less ABPM that has the potential to change the use paradigm for measuring ambulatory blood pressure. We see numerous applications for this technology in the new field of renal denervation (RDN) as well as long term monitoring of post-cardiac procedure and CHF patients following discharge from the hospital,” said Mr. Cohen. “I look forward to collaborating with the management team to support the company’s mission to change the way patients are monitored.” Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of life science industry experience. Cohen currently serves on the boards of several innovative healthcare companies, including Kestra (Nasdaq: KMTS); InspireMD (Nasdaq: NSPR); RxSight (Nasdaq: RXST), Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. Mr. Cohen also serves as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners. About BioBeat Technologies, Ltd BioBeat based in Israel and Boca Raton, FL is a privately held company that has developed wearable, non-invasive cuffless ambulatory blood pressure monitoring technology that enables continuous, blood pressure measurements, respiratory rate, Sp02, ECG, pulse rate, body temperature, stroke volume, cardiac output, systemic vascular resistance and other key physiological parameters. By comparison, unlike traditional ABPM system, BioBeat offers a cuff-less small unobtrusive “patch” device with enhanced patient comfort, especially during sleep while collecting and transmitting real time data to a mobile app. Biobeat’s products are 510(k) cleared by the US Food & Drug Administration.

196

21 Comments

If you’re waiting to start M&A conversations until you're ready to sell, we’ve got intel from 5 medtech CEOs with a track record of medtech exits who may tell you otherwise. They’d probably also tell you that companies that get acquired for the best valuations *start* building relationships with strategics at least 2-3 years before they even consider an exit. For an article I wrote for MassDevice, 5 CEOs who've successfully navigated M&A transactions told me this: The best exits are planned from day one. ➡️ Jennifer Fried (Flow Medical) says that before she even joined her current company, she was already calling potential acquirers. Not to pitch — to listen. "What do you really think about the pulmonary embolism space? What are the big inflection points?" Early conversations helped her understand market dynamics and have shaped the strategy at Flow. ➡️ Joe DeVivo’s (Butterfly Network, Inc.) approach is people-oriented. Joe has delivered 5 exits (!) and he knows M&A is about building relationships, not deal flow. "Simply befriend them. At trade shows, be very open. Keep the dialog going." The onus is on you to help potential buyers understand your business and why it’s worth acquiring. ➡️ James Reinstein (Conformal Medical) emphasizes market selection and timing: "Find a market that's growing fast, has few competitors, and is one that investors want to be in." The idea is to position yourself as part of a growing pie and then show acquirers you’re continually hitting key milestones. ➡️ Cary Vance (previously PhotoniCare, Inc.) says it’s important to cultivate relationships with multiple strategics, but is quick to point out that deals are never guaranteed. "Run your company as if you're going to make a go of it alone — don't count on an acquisition as your rescue plan." ➡️ Nitin Salunke (Supira Medical) says identifying an end goal as early as possible will put you at an advantage:  "Don't go fishing for deals. Make incremental progress on strategics' watch lists, rising from bottom to top." Let value guide your company’s trajectory and align your milestones with that to make the business acquisition-worthy. Simply put: You want your business to get bought, not sold. Strategics are rarely lining up to buy companies that are desperate to be acquired. But startups focused on building great businesses while cultivating the right relationships? They get bought. In short, this is what separates the successful exits from the failed attempts: - They educate potential acquirers without being pushy  - They understand that timing matters as much as value - They pick fast-growing markets with limited competition - They build companies strong enough to survive independently  - They align major conversations with their strongest milestones Check out the full article through the link in the comments. And last, big thanks to Chris Newmarker for your publishing support!

244

28 Comments

The future of Medtech is converging in Dana Point in just 30 days. And the capital is showing up. Partnering is now open for LSI USA ‘25, and calendars are already filling up. It’s not too late to jump in. Some key numbers: Innovators: - 360+ Presenting Companies – those that have disclosed financials have already raised $7.97B and are collectively raising another $4.96B right now. Breakdown by stage: - Later Stage: 39 companies, raising an average of $50M - Series C: 30 companies, raising an average of $29M - Series B: 76 companies, raising an average of $21M - Series A: 129 companies, raising an average of $12M - Seed/Pre-Seed: 66 companies, raising an average of $3.6M Geographic breakdown: - United States: 64% of startups | 84% of investors/strategics - Europe: 19% of startups | 10% of investors - Canada/APAC/Israel: 17% of startups (Canada: 20 | APAC: 28 | Israel: 16) But here’s the most important signal: We're on track for a 1-to-1 Investor/Strategic to Startup Ratio. This is good momentum for our industry. See you in Dana Point. Join us: https://lnkd.in/e9SaGB2h

61

2 Comments

Forbes’ predictions highlight digital health as essential for future-proofing healthcare. At Acarix, we're transforming cardiac care through AI-driven non-invasive diagnostics. The key is ensuring that technological advances enhance access and compassion in patient care. As leaders, we must advocate for a balanced integration of tech into healthcare. #FutureOfHealthcare #AILeadership #CardiacCare https://lnkd.in/gHuBKZUY

54

2 Comments

MedTech Innovation at TCT 2025 🚀 Honored to join the opening session of the MedTech Innovation Forum at TCT 2025, alongside visionary leaders Andrew Cleeland Jan Garfinkle Josh Makower Todd Brinton, MD Amr Salahieh. The session — “So, You Want to Be an Innovator: Master the Process, Channel the Genius” — offered timely reflections on how MedTech innovation must evolve to stay relevant and sustainable. 💡 Key takeaways: 1️⃣ MedTech funding is shifting. The cost of innovation is rising — driven by inflation, higher expectations, and reimbursement delays — making exits slower and returns smaller. Venture capital has shifted toward later-stage, de-risked ideas, creating new challenges for early innovators. 2️⃣ Innovation is a disciplined process, not a stroke of genius. The idea is only a small piece of the puzzle; history is written by those who show up. Unmet clinical needs are abundant, but the most promising ones are often latent—unseen yet impactful. Uncovering them is what leads to truly disruptive innovation. 3️⃣ Innovation thrives on meaning. For physicians, purpose (vs financial gain) is the most powerful motivator. However, deeper understanding and skillful navigation of the complex innovation ecosystem are needed to turn that purpose into lasting impact. In the end, meaningful innovation requires a convergence of insight, discipline, and purpose. #TCT2025 #MedTech #Innovation #MedicalDevices #Biodesign Mayo Clinic Fogarty Innovation Cardiovascular Research Foundation Juan Granada Shai Ran Sapir Lisa Carmel Charanjit (Chet) Rihal Stanford Mussallem Center for Biodesign

196

7 Comments

"ECG diagnostics software platform AccurKardia and cardiac medical technology company HeartBeam Inc. (NASDAQ: BEAT) are joining forces to make AccurKardia's ECG analysis software available on HeartBeam's devices. HeartBeam's cable-free, 12-lead ECG system captures electrical signals from the heart from three directions to assess arrhythmias. The platform is designed for portable devices so physicians can identify cardiac health trends and acute conditions wherever patients are." AccurKardia is an American Heart Association & MedTech Innovator innaugural "Heart & Brain" startup accelerator alumni company! Heart Rhythm Society #HRX2025 #epeeps LSI MedTech World MedTech Strategist European Society of Cardiology EHRA President American College of Cardiology

54

Some really neat new technology was recently unveiled at CHOC Children's, the only #pediatric imaging facility in Orange County. The new gamified #imaging suite from Philips Imaging is helping take the anxiety out of getting #MRI scans for kids, and includes an app, a 'kitten scanner' that lets kids use a miniature version on a toy to get familiar with the process and immersive experiences throughout. Moreover, it will help alleviate the ever-growing demand for pediatric imaging in the county. Andrew Ruiz director of imaging services and Dr. Azam Eghbal, medical director of pediatric radiology, go into more detail in this great new reporting from Yuika Y. for Orange County Business Journal.

38

1 Comment

Had the pleasure of sitting down with Dave Coffaro from the Greater Irvine Chamber to talk about medtech innovation globally and in Orange County —specifically, the potential of therapeutic ultrasound to transform care. We discussed how non-invasive technologies like ours can help patients avoid surgery, reduce risk, and improve outcomes—while also strengthening Orange County’s role as a hub for health innovation. I’m especially glad to see that the Greater Irvine Chamber has identified MedTech as a top industry focus in its strategic plan for regional growth. MedTech doesn’t just save and improve lives—it drives innovation, fuels economic development, and creates high-paying jobs. Grateful for the Chamber’s leadership in supporting our growing medtech ecosystem. The future of healthcare is being built right here. Listen now on the app, website, or your favorite podcast platform: https://lnkd.in/gCevh4Ag #MedTech #Innovation #TherapeuticUltrasound #NonInvasiveCare #OrangeCounty #HealthcareLeadership #EconomicGrowth

59

3 Comments

Rethinking Heart Failure Management—Why Device Innovation Matters Interesting article from the Cleveland Clinic - Device-Based Heart Failure Therapies in the Spotlight. It highlights the shift in how we address heart failure in today’s clinical landscape. The piece emphasizes that despite advances in pharmacotherapy, hospitalisation and mortality rates continue to climb—and that earlier consideration of device-based therapies is essential to alter disease trajectories effectively. This aligns with the latest consensus guidance from the HFSA, advocating a more integrated pathway that pairs guideline-directed medical therapy (GDMT) with device-based options for patients not fully responding to medications alone. From my perspective at Ceryx Medical, this trend holds deep relevance. Our device, designed to optimise cardiac function, improve energy efficiency and boost cardiac output thereby treating symptoms and inducing cardiac repair, dovetails with this evolving paradigm. Here’s why: Early intervention is key: By targeting the root of cardiac inefficiency sooner, our device aligns with the Cleveland Clinic’s call to shift device therapy “earlier” in the care continuum, particularly in NYHA II–III patients. Bridging gaps in GDMT response: For patients who remain symptomatic despite medical management our approach offers a powerful tool for eliminating the debilitating symptoms of heart failure. Enhancing personalization of care: The trend toward phenotype-driven treatment decisions, as outlined in recent reviews, mirrors our commitment to developing solutions that fit the individual patient’s physiology, symptom profile, and treatment tolerance. Complementary rather than competitive: Ceryx has demonstrated our technology significant improves the clinical condition of subjects already treated with optimal pharmacotherapy. In essence, this Cleveland Clinic article reinforces that advanced device strategies are not just “nice to have”—they’re becoming essential companions to pharmacological therapy in improving outcomes and quality of life for heart failure patients. #HeartFailure #MedicalDevices #DigitalHealth #ClinicalInnovation #Cardiology #GDMT #DeviceTherapy #PatientCentricCare

34

What would you do if you were 32 years old and handed $150M in responsibility? That’s exactly the position Gary Thomas, the SVP of Manufacturing/Product Development at Onkos Surgical found himself in... leading multiple business units across MedTech with barely a decade of experience under his belt. No manual. No roadmap. Just grit, great people, and an insane amount of determination to not let it fall apart. In our recent episode of 𝐓𝐡𝐞 𝐌𝐞𝐝-𝐓𝐞𝐜𝐡 𝐓𝐚𝐥𝐞𝐧𝐭 𝐋𝐚𝐛 podcast, Gary shared how those early high-pressure years shaped the leader he is today and how the lessons from that time still serve him when product launches go sideways or when team members say, “this can’t be done.” Support. Vigilance. Determination. That’s how you lead when the stakes are high and the clock is ticking. Leadership isn’t about having all the answers. It's about having the backbone when others doubt, and the humility to lean on the people around you. If you're a MedTech leader navigating complex product launches and looking for real talk on what it actually takes to lead under pressure… this is an episode you won't want to miss! Thanks for being a valued guest on the show Gary! -MR 𝐏𝐒 Link to full episode and all the others in the comments. #podcast #medtechtalentlab #leadership #hiring #recruiting

79

11 Comments

💡 𝗕𝗶𝗴 𝘀𝘁𝗲𝗽 𝘁𝗼𝘄𝗮𝗿𝗱 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗜 ? A new bipartisan bill (S.1399, the Health Tech Investment Act) would create a dedicated Medicare pathway for FDA‑cleared AI devices: - Automatic Category III NTAPC codes valid for 5 years - Payments based on the manufacturer’s cost estimate - Smoother transition to permanent CPT codes Backed by GE HealthCare, Siemens Healthineers, the proposal could finally solve the “great technology, no reimbursement” dilemma that slows AI adoption. Still early days, but encouraging to see Congress address the business model behind clinical AI. Full story via Brian Casey / The Imaging Wire Wire 👉 https://lnkd.in/eRrdMeT3 #MedicalAI #AI #Radiology #HealthPolicy

48

3 Comments

CODING UPDATE! U.S. Centers for Medicare & Medicaid Services (CMS) has issued a transitional pass-through payment billing code specifically for absorbable bone fixation screws and anchors.  The C1741 HCPCS code recognizes the patient benefit offered by innovative non-permanent implants, such as OSSIOfiber Compression Screws, by facilitating pass-through payments to hospitals and ASCs. Stay tuned for coding guide...  

216

6 Comments

The University of Miami’s new research demonstrates how continuous glucose monitors are expanding beyond diabetes management into broader healthcare. Now nephrologists, sleep specialists, and gastroenterologists are using CGM data to guide treatment decisions. This cross-specialty adoption highlights an important truth: when glucose data is accurate and reliable, it transforms care across multiple conditions. Imagine the possibilities when we eliminate the 10-15 minute lag of current wearable technology. Read more at: https://lnkd.in/gwif_mvP #Diabetes #DiabetesCare #HealthTech #CGM #CBGM

69